达格列净二甲双胍与西格列汀二甲双胍治疗新诊断2型糖尿病的疗效比较

Afra Ishtiaque, Shahreen Mehmood Khan, S. Azhar, M. Mehmood, Saira Shahnawaz
{"title":"达格列净二甲双胍与西格列汀二甲双胍治疗新诊断2型糖尿病的疗效比较","authors":"Afra Ishtiaque, Shahreen Mehmood Khan, S. Azhar, M. Mehmood, Saira Shahnawaz","doi":"10.53350/pjmhs221610459","DOIUrl":null,"url":null,"abstract":"Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin","PeriodicalId":296492,"journal":{"name":"Pakistan Journal of Medical &amp; Health Sciences","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Comparison of the Efficacy of Dapagliflozin Metformin Versus Sitagliptin Metformin: in Newly Diagnosed Type 2 Diabetes\",\"authors\":\"Afra Ishtiaque, Shahreen Mehmood Khan, S. Azhar, M. Mehmood, Saira Shahnawaz\",\"doi\":\"10.53350/pjmhs221610459\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin\",\"PeriodicalId\":296492,\"journal\":{\"name\":\"Pakistan Journal of Medical &amp; Health Sciences\",\"volume\":\"39 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pakistan Journal of Medical &amp; Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53350/pjmhs221610459\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical &amp; Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53350/pjmhs221610459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:比较达格列净+二甲双胍与西格列汀+二甲双胍治疗新诊断的2型糖尿病的疗效。方法:在这项随机对照试验中,我们共纳入180例;根据计算机生成的随机化表,将90例新诊断为2型糖尿病(HbA1c>6.5)的患者分为a、b两组。A组患者每日服用西格列汀100mg,外加850 mg,二甲双胍500mg,每日2次。B组患者给予达格列净10mg / d +二甲双胍500mg / d,每日2次,连用6个月。每月对患者进行随访,以防出现不便。最后一次随访于治疗第6个月进行。所有不良/不依从性的患者均被排除在研究之外。所有HbA1c <6.0的病例均视为有效治疗患者。结果:两组疗效比较:A组44例(48.9%),B组31例(34.4%),总疗效41.7%,p值=0.0.35,差异有统计学意义。结论:达格列净+二甲双胍治疗新诊断2型糖尿病的疗效显著高于西格列汀+二甲双胍。关键词:新诊断2型糖尿病,治疗,达格列净+二甲双胍Vs西格列汀+二甲双胍
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Comparison of the Efficacy of Dapagliflozin Metformin Versus Sitagliptin Metformin: in Newly Diagnosed Type 2 Diabetes
Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
An Audit of Injuries Sustained in Two–Wheeler Accidents in the Metropolitan City of Karachi, Pakistan Real World Data about the Characteristics of Adult Diabetes Mellitus Patients Visiting Outpatient Department of a Tertiary Care Hospital Randomized Controlled Clinical Trial to Examine the Efficacy of Oral Midazolam in Post Operative Pain Reduction in Patients Undergoing Laparoscopic Cholecystectomy Effect of Low Dose (100mg/kg) of Zinc Telluride (ZnTe) on Hematology of Male Albino Mice (Mus musculus) Evaluation of Diagnostic Accuracy of Typhidot Test Against Blood Culture in Diagnosis of Enteric Fever
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1